Novartis' position about this year's price increase has been announced during the Q2 2018 earnings call transmitted as a live audio webcast.
The company also said it will not raise the average price of the drugs it sells beyond the annual rate of inflation in the United States and will continue to "evaluate our portfolio to look for opportunities to further reduce costs".
Swiss drugmaker Novartis said on Tuesday it would not raise prices on its USA products for the remainder of the year, following a similar move by Pfizer the week prior.
The move by Merck comes after Pfizer announced price hikes for almost three dozen drugs only to reverse course amid public pressure from President Donald Trump.
Pfizer moved on July 1 to raise the prices on 41 drug products.
Trump's administration outlined a plan for lower prices a few months ago.
Amid growing pressure by the Trump administration to reduce drug prices for USA patients, Merck has announced that the company will not increase the average net price across their product portfolio by more than inflation annually. "Likewise to Pfizer. We are making a big push to actually reduce the prices, maybe substantially, on prescription drugs", Trump said in a Thursday tweet.
Last night also Merck & Co responded to the president's appeal.
Another drug company is promising to cut prices on some medications.
The New Jersey-based drugmaker will slash its hepatitis C treatment Zepatier by 60 percent and will lower the list price of six other drugs by 10 percent.
Pharmaceutical Research and Manufacturers of America spent $5.54 million between April and June, down 7.7 percent from the same period a year ago, according to disclosures released by the federal government on Friday.
In May, Health and Human Services Secretary Alex Azar published "American Patients First", a blueprint detailing plans to lower prices and out-of-pocket costs by lifting rules preventing government health programs from securing deep discounts and introducing incentives for drug-makers.